Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2013-12-10

Clinical Trial Update: Safety Extension Study Of Leuprolide Acetate (Lupron Depot) In The Treatment Of Central Precocious Puberty [Phase 3]

View source ↗

Summary

A completed Phase 3 safety-extension trial evaluated leuprolide acetate (Lupron Depot) for central precocious puberty, with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LUPRON DEPOT (LEUPROLIDE ACETATE)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Precocious, Leuprolide Acetate | Phase 3 | Status: COMPLETED | Results posted: 2013-12-10